Valiant Organics Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹304 Cr +93.6% YoYSee revenue, profit and what management said. You are viewing Q4 FY24.
VO

Valiant Organics Ltd

Q4 FY24Chemicals & Petrochemicals

Valiant Organics Q4 FY24 earnings call: Revenue & Margins

Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹177Cr
+25.5% QoQ
Net profit
−₹20Cr
Margin
−1.2%
−3 pp QoQ

Valiant Organics Ltd Q4 FY24 key numbers

Revenue
Standalone Revenue from Operations for FY24: INR 6,772 million, down from INR 9,116 million in FY23.

As stated in Valiant Organics Ltd's Q4 FY24 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Valiant Organics Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹411
Market cap₹1.2K Cr
P/E23.7

The short version

Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year. EBITDA for Q4 FY24: INR 396 Mn (Standalone), INR 382 Mn (Consolidated); standalone EBITDA margin 5.85%, consolidated 5.28%. - Year-on-year EBITDA decline: Standalone EBITDA down from INR 1,299 Mn in FY23 to 396 Mn in FY24; margin dropped from 14.25% to 5.85%.

From Valiant Organics Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year.
  • Standalone Revenue from Operations for FY24: INR 6,772 million, down from INR 9,116 million in FY23.
  • EBITDA for Q4 FY24 (consolidated): INR 382 million, significantly down from INR 1,643 million in FY23.

2 more points from Valiant Organics Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ortho Amino Phenol (OAP) project:
  • Status: Expected to commence soon; trial run successful but further improvement needed.
  • Purpose: Currently entirely imported in India; part of production to be used for forward integration of an existing product.
  • Chlorophenol capacity expansion:
  • Environmental approval obtained to increase capacity to 21,600 MTPA (page 7).
  • PAP factory:
  • Phase 1 completed and production ramped up to over 400 MT per month; multipurpose pharma intermediates plant commenced development (page 7).
  • Investment figures:

2 more points from Valiant Organics Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Valiant Organics Ltd said on order book & pipeline — free account, 30 seconds.

Valiant Organics Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Valiant Organics Ltd Q4 FY24 results — key figures

Valiant Organics Ltd Q4 FY24 reported results vs year-ago quarter, ₹ crore
₹ CrQ4 FY24Q3 FY24QoQ
Revenue177141+25.5%
Operating profit (EBITDA)-23-166.7%
Operating margin-1.2%1.8%-3 pp
Profit before tax-25-10—
Net profit (PAT)-20-8—
EPS (₹)-7.32-2.86—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹304 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Gujarat Alkalies (Q4 FY24)

    951.17 Crores (Page 8) . Key concall takeaways from Gujarat Alkalies & Chemicals Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

  • Himadri Special (Q4 FY24)

    1,176.95 Cr, up 14.39% YoY from Rs. Key concall takeaways from Himadri Speciality Chemical Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

  • Chemcon Speciality Chemicals (Q4 FY24)

    Q4 FY24 Revenue from Operations: Rs 59.6 Cr, down 24.6% YoY from Rs 79.1 Cr in Q4 FY23 (Page 8, 6) . Key concall takeaways from Chemcon Speciality Chemicals…

  • Excel Industries (Q4 FY24)

    Q4 FY24 revenue: ₹233.5 Cr, a 3.3% increase quarter-on-quarter and a 29.5% increase year-on-year (Page 11, 9, 7, 5). Key concall takeaways from Excel…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Valiant Organics Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Valiant Organics Ltd Q4 FY24 results?

Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year. EBITDA for Q4 FY24: INR 396 Mn (Standalone), INR 382 Mn (Consolidated); standalone EBITDA margin 5.85%, consolidated 5.28%. - Year-on-year EBITDA decline: Standalone EBITDA down from INR 1,299 Mn in FY23 to 396 Mn in FY24; margin dropped from 14.25% to 5.85%.

What is Valiant Organics Ltd share price analysis?

Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.

Is Valiant Organics Ltd planning capital expenditure?

Ortho Amino Phenol (OAP) project: - Status: Expected to commence soon; trial run successful but further improvement needed.

Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.